We highly recommend enabling Javascript while using the BlackBoxRX site.


Serious Infections Caused By Encapsulated Bacteria

Meningococcal infections may occur in patients treated with EMPAVELI and may become rapidly life-threatening or fatal if not recognized and treated early. Use of EMPAVELI may predispose individuals to serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis types A, C, W, Y, and B, and Haemophilus influenzae type B. (5.1).

  • Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria. (5.1) •
  • Vaccinate patients against encapsulated bacteria as recommended at least 2 weeks prior to administering the first dose of EMPAVELI unless the risks of delaying EMPAVELI therapy outweigh the risks of developing a serious infection. See Warnings and Precautions (5.1) for additional guidance on managing the risk of serious infections.
  • Vaccination reduces, but does not eliminate, the risk of serious infections. Monitor patients for early signs of serious infections and evaluate immediately if infection is suspected. (5.1)

EMPAVELI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the EMPAVELI REMS, prescribers must enroll in the program. (5.2) 

Approved Risk Evaluation and Mitigation Strategies (REMS)

EMPAVELI (Pegcetacoplan) Injection

Patient Counseling Information

Package Inserts


Updated June 2021